Introduction {#s1}
============

Insulin is secreted from pancreatic β-cells and acts on target tissues such as muscle and liver to regulate blood glucose. Secretion of insulin occurs by regulated exocytosis, whereby secretory granules containing the hormone and other bioactive peptides and small molecules fuse with the plasma membrane. The first aqueous contact between granule lumen and the extracellular space is a narrow fusion pore (upper limit 3 nm; [@bib3]) that is thought to consist of both lipids and proteins ([@bib11]; [@bib69]). At this stage, the pore acts as a molecular sieve that allows release of small transmitter molecules such as nucleotides and catecholamines, but traps larger cargo ([@bib56]; [@bib13]; [@bib52]; [@bib6]). Electrophysiological experiments have shown that the fusion pore is short-lived and flickers between closed and open states, suggesting that mechanisms exist that stabilize this channel-like structure and restrict pore expansion ([@bib52]; [@bib33]; [@bib17]; [@bib51]). The pore can then expand irreversibly (termed full fusion), which leads to mixing of granule and plasma membrane and release of the bulkier hormone content ([@bib56]; [@bib13]; [@bib7]). Alternatively, the pore can close indefinitely to allow the granule to be retrieved, apparently intact, into the cell interior (termed kiss-and-run or cavicapture) ([@bib56]; [@bib52]; [@bib75]; [@bib79]; [@bib71]). Estimates in β-cells suggest that 20--50% of all exocytosis in β-cells are transient kiss-and-run events that do not lead to insulin release ([@bib56]; [@bib52]). However, kiss-and-run exocytosis contributes to local signaling within the islet because smaller granule constituents, such as nucleotides, glutamate or GABA, are released even when the fusion pore does not expand. Within the islet, ATP synchronizes β-cells ([@bib35]), and has both inhibitory ([@bib64]; [@bib59]) and stimulatory ([@bib62]) effects on insulin secretion. ATP suppresses glucagon release from α-cells ([@bib80]), and activates macrophages ([@bib83]). Interstitial GABA leads to tonic GABA-A receptor activation and α-cell proliferation ([@bib43]; [@bib14]), and glutamate stimulates glucagon secretion ([@bib18]).

Regulation of fusion pore behavior is not understood mechanistically, but several cellular signaling events affect both lifetime and flicker behavior. Pore behavior has been shown to be regulated by cytosolic Ca^2+^, cAMP, PI(4,5)P~2~, and activation of protein kinase C (PKC) ([@bib52]; [@bib33]; [@bib5]; [@bib20]; [@bib65]) and recent superresolution imaging indicates that elevated Ca^2+^ and dynamin promote pore closure ([@bib71]; [@bib21]). Both myosin and the small GTPase dynamin are involved in fusion pore restriction ([@bib41]; [@bib78]; [@bib32]; [@bib10]; [@bib9]), and assembly of filamentous actin promotes fusion pore expansion ([@bib84]), suggesting a link to endocytosis and the cytoskeleton. In β-cells of type-2 diabetics, upregulation of amysin leads to decreased insulin secretion because fusion pore expansion is impaired ([@bib22]), and the Parkinson's related protein α-synuclein promotes fusion pore dilation in chromaffin cells and neurons ([@bib50]), thus providing evidence for altered fusion pore behavior in human disease.

Inadequate insulin secretion in type-2 diabetes (T2D) is treated clinically by two main strategies. First, sulfonylureas (e.g. tolbutamide and glibenclamide) close the K~ATP~ channel by binding to its regulatory subunit SUR1, which leads to increased electrical activity and Ca^2+^-influx that triggers insulin secretion ([@bib36]). Sulfonylureas are given orally and are first-line treatment for type-2 diabetes in many countries. Second, activation of the receptor for the incretin hormone glucagon-like peptide 1 (GLP-1) raises cytosolic \[cAMP\] and thereby increases the propensity of insulin granules to undergo exocytosis. Both peptide agonists of the GLP-1 receptor (e.g. exendin-4) and inhibitors of DPP-4 are used clinically for this purpose. The effect of cAMP on exocytosis is mediated by a protein-kinase A (PKA)-dependent pathway, and by Epac2, a guanine nucleotide exchange factor for the Ras-like small GTPase Rap ([@bib45]) that is a direct target for cAMP ([@bib57]) and is recruited to insulin granule docking sites ([@bib4]). Epac2 has also been suggested to be activated by sulfonylureas ([@bib87]), which may underlie some of their effects on insulin secretion.

Here, we have studied fusion pore regulation in pancreatic β-cells, using high-resolution live-cell imaging. We report that activation of Epac2, either through GLP1-R/cAMP signaling or via sulfonylurea, restricts expansion of the insulin granule fusion pore by recruiting dynamin and amisyn to the exocytosis site. Activation of this pathway by two classes of antidiabetic drugs therefore hinders full fusion and insulin release, which is expected to reduce their effectiveness as insulin secretagogues.

Results {#s2}
=======

cAMP-dependent fusion pore restriction is regulated by Epac but not PKA {#s2-1}
-----------------------------------------------------------------------

To monitor single granule exocytosis, human pancreatic β-cells were infected with adenovirus encoding the granule marker NPY-Venus and imaged by TIRF microscopy. Exocytosis was evoked by local application of a solution containing 75 mM K^+^, which leads to rapid depolarization and Ca^2+^ influx. Visually, two phenotypes of granule exocytosis were observed. In the first, termed full fusion, fluorescence of a granule that was stably situated at the plasma membrane suddenly vanished during the stimulation (in most cases within \<100 ms; [Figure 1a--c](#fig1){ref-type="fig"}, left panels). Since the EGFP label is relatively large (3.7 nm vs 3 nm for insulin monomers), this is interpreted as rapid pore widening that allowed general release of granule cargo. The sudden release of material may suggest that this release coincided with the collapse of the granule into the plasma membrane, but we cannot exclude that at least some granules remained intact ([@bib75]; [@bib71]; [@bib78]; [@bib39]). In the second type, the rapid loss of the granule marker was preceded by an increase in its fluorescence that could last for several seconds (flash events, [Figure 1a--c](#fig1){ref-type="fig"}, right panels). We and others have previously shown ([@bib75]; [@bib26]; [@bib29]) that this reflects neutralization of the acidic granule lumen and dequenching of the EGFP-label, before the labeled cargo is released. Since this neutralization occurs as the result of proton flux through the fusion pore, the fluorescence timecourse of these events can be used to quantitatively study fusion pore behavior.

![cAMP-dependent fusion pore restriction depends on Epac (but not PKA).\
(**a**) Examples of single granule exocytosis in human β-cells expressing NPY-Venus and challenged with 75 mM K^+^. Full fusion (left) and flash event (right), where sudden loss of the granule label was preceded by a transient fluorescence increase. Arrows indicate moment of fusion pore opening (orange) and content release (blue). (**b**) Cartoons illustrating the interpretation of events in a. (**c**) Fluorescence time courses for the events in b. Overlaid (green) are fitted functions used to estimate NPY release time. (**d**) Fraction of flash events in experiments as in a-c, in cells exposed to the indicated agents; forskolin (fsk, p=0.01 vs ctrl), exendin-4 (Ex4, p=0.02 vs ctrl), ESI-09 (p=3\*10^−4^ vs fsk), S223 (p=0.04 vs ctrl), fsk +S223 (p=0.99 vs fsk), RP-8 (p=0.91 vs fsk) and Rp-8 +S223 (p=0.19 vs ctrl; Kruskal Wallis/Dunn). Number of donors analyzed: 7 (CTR); 5 (fsk); 4 (Ex4); 7 (fsk +ESI09); 6 (S223); 6 (fsk +S223); 7 (RP-8); 4 (Rp-8 +S223). n, number of cells. (**e**) Cumulative frequency histograms of NPY release times; fsk (p=9\*10^−7^ vs ctrl), Ex4 (p=1\*10^−6^ vs ctrl), ESI-09 (p=2\*10^−4^ vs fsk), S223 (p=4\*10^−6^ vs ctrl),Fsk +S223 (n.s. vs fsk), RP-8 (n.s. vs fsk) and RP-8 +S223 (p=0.016 vs ctrl); Kolmogorov-Smirnov test). Inset shows median NPY release times for 170 (CTR), 197 (fsk), 155 (Ex4), 81 (ESI-09), 240 (S223), 328 (fsk +S223), 277 (RP-8) and 227 (Rp-8 +S223) events. (**f**) Exocytosis during 40 s of K^+^-stimulation for control (CTR) and with forskolin (fsk, 2 µM, p=0.002 vs ctrl; Kruskal Wallis/Dunn) or Exendin-4 (Ex4, 10 nM, p=0.005 vs ctrl) or S223 (5 µM, p=0.002 vs ctrl) or RP-8 +S223 (p=0.012 vs ctrl and n.s. vs S223) in the bath solution. Inhibitors of Epac (ESI-09, 10 µM, p=9\*10^-^7 vs fsk) or PKA (RP-8, 100 µM, n.s. vs fsk) or Epac2 activator S223 (n.s. vs fsk), one-way ANOVA with Games-Howell post hoc test) were supplied in addition to forskolin. Flash exocytosis (in color) and full fusions (in white) are shown separately. n, number of cells.](elife-41711-fig1){#fig1}

In the following, we will report two parameters that reflect fusion pore behavior, the fraction of exocytosis events with flash phenotype (indicating restricted pores, about 40% in control conditions; [Figure 1d](#fig1){ref-type="fig"}), and the duration of the flash, referred to as 'NPY release times'. The latter was estimated by fitting a discontinuous function to the fluorescence timecourse (see [Figure 1c](#fig1){ref-type="fig"}, green lines and [Figure 1e](#fig1){ref-type="fig"}), which limits the analysis to granules that eventually released their peptide content. The distribution of the NPY release times followed a mono-exponential function and was on average 0.87 ± 0.12 s (186 granules in 26 cells) in control conditions ([Figure 1e](#fig1){ref-type="fig"}). Such events are increased by elevated cAMP ([@bib52]; [@bib33]) and likely other conditions that stabilize the fusion pore. Indeed, when forskolin (2 µM; fsk) was added to the bath solution we observed a twofold increase of exocytosis rate ([Figure 1f](#fig1){ref-type="fig"}), a threefold increase of NPY release times ([Figure 1e](#fig1){ref-type="fig"}), and a nearly doubled fraction of events with restricted fusion pores ([Figure 1d,f](#fig1){ref-type="fig"}). The GLP-1 agonist exendin-4 (10 nM; Ex4) had comparable effects ([Figure 1d--f](#fig1){ref-type="fig"}). Effects similar to those observed for human β-cells ([Figure 1](#fig1){ref-type="fig"}) were observed in the insulin secreting cell line INS-1 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

The effect of fsk on fusion pore behavior was mimicked by the specific Epac2 agonist S223 ([@bib66]). Incubation with S223-acetomethoxyester (5 µM) increased the fraction of flash events by 60% ([Figure 1d](#fig1){ref-type="fig"}), doubled average NPY release times ([Figure 1e](#fig1){ref-type="fig"}) and doubled the event frequency ([Figure 1f](#fig1){ref-type="fig"}); the effects of fsk and S223 were not additive. In contrast, the Epac-inhibitor ESI-09 decreased the exocytosis rate in the presence of fsk by 80% ([Figure 1f](#fig1){ref-type="fig"}), and the average NPY release time and the fraction of flash events were both reduced by 60% ([Figure 1d--e](#fig1){ref-type="fig"}). PKA inhibition with Rp8-Br-cAMPS ([@bib30]) decreased neither the fraction of flash events, nor average NPY release times ([Figure 1e](#fig1){ref-type="fig"}). The results indicate that Epac rather than PKA is responsible for cAMP-dependent fusion pore regulation. Paradoxically, Epac activation increases the rate of exocytosis but slows the rate of peptide release from individual granules.

Epac2 overexpression restricts fusion pores and prolongs their lifetime {#s2-2}
-----------------------------------------------------------------------

We studied the effect of Epac2 overexpression on fusion pore regulation. INS-1 cells were co-transfected with EGFP-Epac2 and NPY-tdmOrange2 and fluorescence was recorded simultaneously in both color channels. Epac2 overexpression had no effect on the overall exocytosis rate in either absence or presence of fsk ([Figure 2a](#fig2){ref-type="fig"}), but increased the rate of flash events ([Figure 2b--c](#fig2){ref-type="fig"}), supporting our finding, based on manipulation of the endogenous Epac2 activity, that Epac2 is involved in fusion pore regulation ([Figure 1d](#fig1){ref-type="fig"}). NPY release times in cells overexpressing Epac2 increased threefold in the absence of fsk, and were similar to controls in presence of fsk ([Figure 2d](#fig2){ref-type="fig"}). This indicates that a high Epac concentration can achieve sufficient activity to affect insulin secretion even at basal cAMP level, likely because cAMP acts in part by increasing the Epac concentration at the plasma membrane ([@bib4]).

![Epac2 overexpression prolongs NPY release times.\
(**a**) Cumulative exocytosis in INS-1 cells stimulated with 75 mM K^+^; gray for control cells, purple for cells expressing Epac2-EGFP (both also expressed NPY-tdmOrange2); fsk indicates forskolin in the bath solution. CTR, n = 13 (4 preps); Epac2, n = 11 (2 preps); CTR +fsk, n = 15 (5 preps); Epac2 +fsk, n = 14 cells (2 preps). (**b**) Total exocytosis in (**a**), separated into flash events (color) and full fusion (white). Epac2 expression reduced full fusion events (no fsk p=0.06; with fsk p=0.01, Kruskal Wallis/Dunn). n, number of cells. (**c**) Fraction of flash events in (**a--b**). (Kruskal Wallis/Dunn). n, number of cells. (**d**) NPY release times for conditions in a-c. Epac overexpression increased NPY release times in absence (p=0.014) but not in presence of fsk (p=0.87, Kolmogorov-Smirnov test). Inset shows the NPY release times for 38 (CTR), 27 (Epac2), 119 (CTR +fsk) and 77 (Epac2 +fsk) events.](elife-41711-fig2){#fig2}

ATP release is accelerated upon Epac inhibition {#s2-3}
-----------------------------------------------

To test if cAMP-dependent fusion pore restriction affects release of small transmitter molecules, we quantified nucleotide release kinetics from individual granules using patch clamp electrophysiology. The purinergic receptor cation channel P2X~2~, tagged with RFP (P2X~2~-RFP), was expressed in INS-1 cells as an autaptic nucleotide sensor ([@bib56]) ([Figure 3a](#fig3){ref-type="fig"}). The cells were voltage-clamped in whole-cell mode and exocytosis was elicited by including a solution with elevated free Ca^2+^ (calculated 600 nM) in the patch electrode. In this configuration, every exocytosis event that co-releases nucleotides causes an inward current spike, similar to those observed by carbon fiber amperometry ([Figure 3a--b](#fig3){ref-type="fig"}). Including cAMP in the pipette solution increased the frequency of current spikes by 50%, consistent with accelerated exocytosis. This effect of cAMP was blocked if the Epac inhibitor ESI-09 was present ([Figure 3b--c](#fig3){ref-type="fig"}). The current spikes (see [Figure 3a](#fig3){ref-type="fig"}, right) reflect nucleotide release kinetics during individual exocytosis events. In the presence of cAMP, but not cAMP + ESI-09, they were markedly widened as indicated by on average 20% longer half-widths ([Figure 3d](#fig3){ref-type="fig"}), 30% longer decay constants (τ, [Figure 3e](#fig3){ref-type="fig"}), and 40% slower rising phases (25--75% slope, [Figure 3f](#fig3){ref-type="fig"}), compared with control. This indicates that nucleotide release is slowed by cAMP, likely because of changed fusion pore kinetics. Since the effect is blocked by ESI-09, we conclude that the cAMP effect probably is mediated by Epac.

![Cytosolic cAMP slows ATP release by activating Epac.\
(**a**) Electrophysiological detection of nucleotide release events in INS-1 cells expressing P2X~2~-RFP. Cartoon of the assay (left) and example current spike (black) with fit and analysis parameters (red; T~half~, tau and slope during 25% to 75% of peak). (**b**) Representative P2X~2~ currents for control (black), and with cAMP (green) or with cAMP together with ESI-09 (purple) in the electrode solution. (**c**) Spike frequency conditions in (**b**). n of events (on top) and n of cells (on bars); two preps for each condition. (**d--f**) Cumulative frequency histograms of spike half width (**d**), decay constant tau (**e**), and slope of the rising phase (25% and 75% of peak, (**f**)) for CTR (n = 410 spikes, 14 cells), +cAMP (n = 1240, 14 cells) and +ESI-09 + cAMP (n = 552, 15 cells) with medians in the insets. cAMP increased half-width (p=4.1\*10^−31^ vs ctrl, Kolmogorov-Smirnov test), tau (p=2.7\*10^−32^, Kolmogorov-Smirnov test), and rising slope (p=4.7\*10^−19^, Kolmogorov-Smirnov test); the effects were reversed by ESI-09 (p=3.4\*10^−21^, p=3.6\*10^−22^, and p=1.3\*10^−9^, Kolmogorov-Smirnov test), respectively.](elife-41711-fig3){#fig3}

cAMP-dependent fusion pore regulation is absent in Epac2^-/-^ (*Rapgef4*^-/-^) β-cells {#s2-4}
--------------------------------------------------------------------------------------

Since ESI-09 blocks all Epac isoforms ([@bib89]), we characterized fusion pore behavior in isolated β-cells from Epac2^-/-^ (*Rapgef4*^-/-^) mice that lack all splice variants of Epac2 ([@bib47]). Cells from WT or Epac2^-/-^ mice were infected with adenovirus encoding the granule marker NPY-tdmOrange2 and challenged with 75 mM K^+^ ([Figure 4a--b](#fig4){ref-type="fig"}). In the absence of forskolin, exocytosis was significantly slower in Epac2^-/-^ cells than WT cells, and the fraction of flash-associated exocytosis events was five-fold lower ([Figure 4c--e](#fig4){ref-type="fig"}). This was paralleled by strikingly shorter fusion pore life-times in Epac2^-/-^ cells compared with WT ([Figure 4f](#fig4){ref-type="fig"}). The data suggest that Epac2 is partially activated in these conditions, consistent with elevated cAMP levels in mouse β-cells in hyperglycemic conditions ([@bib23]). As expected, forskolin increased both exocytosis ([Figure 4e](#fig4){ref-type="fig"}) and the fraction of flash events ([Figure 4c](#fig4){ref-type="fig"}) of WT cells. In contrast, forskolin failed to accelerate exocytosis in Epac2^-/-^ cells, and the fraction of flash events was similar with or without forskolin ([Figure 4c,f--g](#fig4){ref-type="fig"}). We conclude therefore that the effects of cAMP on fusion pore behavior are mediated specifically by Epac2.

![Fusion pores expand rapidly in Epac2^-/-^ (*Rapgef4*^-/-^) mice.\
(**a--b**) Examples of NPY-tdmOrange2 exocytosis events in β-cells from Epac2^-/-^ mice or from wildtype littermates, stimulated with 75 mM K^+^ in presence of forskolin. Note absence of a flash in Epac2 ko. (**c**) Fraction of flash events for experiments in (**a--b**); differences are significant in absence (p=0.027, Kruskal Wallis/Dunn test) or presence of fsk (p=0.011). Number of mice: 4 (WT); 4 (Epac2 KO); 5 (WT + fsk); 2 (Epac2 KO + fsk). n, number of cells. (**d**) Cumulative exocytosis for experiments in absence of forskolin (a,c left) for wildtype (black) and Epac2^-/-^ cells (red), differences are n.s. (**e**) Cumulative exocytosis for experiments in presence of forskolin (b,c right) for wildtype (black) and Epac2^-/-^ cells (red). p=0.003, Kruskal Wallis/Dunn test. (**f--g**) Cumulative frequency histograms and medians (inset) of NPY release times for exocytotic events in d (no forskolin, 23 events for wt, 22 for Epac2^-/-^) and E (with forskolin, 50 events for wt, nine for Epac2-/-). Differences in f are significant (p=0.043; Kolmogorov-Smirnov test).](elife-41711-fig4){#fig4}

Sulfonylureas delay fusion pore expansion through the same pathway as cAMP {#s2-5}
--------------------------------------------------------------------------

Sulfonylureas have been reported to activate Epac ([@bib87]), in addition to their classical role that involves the sulfonylurea receptor (SUR). We therefore tested the effect of sulfonylureas on fusion pore behavior. INS-1 cells expressing NPY-tdmOrange2 were tested with three types of sulfonylureas, with different relative membrane permeability (tolbutamide \< glibenclamide \< gliclazide). In addition, diazoxide (200 µM) was present to prevent electrical activity. Exocytosis was not observed under these conditions, but could be triggered by local application of elevated K^+^ (75 mM). In the absence of fsk, the sulfonylureas accelerated K^+^-stimulated exocytosis about twofold over that observed in control ([Figure 5b](#fig5){ref-type="fig"}, left), which is consistent with earlier findings that sulfonylureas augment insulin secretion via intracellular targets ([@bib12]). This effect was entirely due to an increase in flash-associated exocytosis events ([Figure 5b--c](#fig5){ref-type="fig"}) and the average NPY release time increased accordingly in the presence of sulfonylurea ([Figure 5d](#fig5){ref-type="fig"}). Fsk strongly stimulated both flash-associated and full fusion exocytosis in absence of sulfonylurea ([Figure 5b--c](#fig5){ref-type="fig"}, middle); under these conditions, sulfonylureas tended to decrease full-fusion exocytosis without effect on the frequency of flash-associated events ([Figure 5b](#fig5){ref-type="fig"}, middle). Accordingly, NPY release times were elevated compared with control (no fsk), and only marginally longer than with fsk alone ([Figure 5d](#fig5){ref-type="fig"}, right). Similar results were obtained in human β-cells, where glibenclamide increased exocytosis in the absence of fsk (p=0.01, n = 13 cells from four donors) but not in its presence (p=0.80, n = 7 cells from four donors; data not shown). The data indicate that sulfonylureas restrict fusion pore expansion through the same intracellular pathway as cAMP, which may counteract their stimulating effect on exocytosis by preventing or delaying peptide release.

![Sulfonylureas cause fusion pore restriction.\
(**a**) Cartoon of the experimental design in (**b--d**). INS-1 cells expressing NPY-tdmOrange2 were bathed in 10 mM glucose, diazoxide (200 µM) and either 200 µM tolbutamide (tolb), 50 µM glibenclamide (glib) or 50 µM gliclizide (gliz); exocytosis was evoked by acute exposure to 75 mM K^+^. (**b**) Exocytosis in absence (left) or presence (right) of fsk (2 µM) for flash events (color) and full fusions (white). Total exocytosis was increased by sulfonylurea in absence of fsk (p=0.15 tolb; p=0.05 glib, p=0.005 gliz, Kruskal Wallis/Dunn test vs ctrl/no fsk), but not in its presence (p=0.23 tolb; p=0.16 glib, p=0.10 glic). Sulfonylurea reduced full fusion events in presence of fsk (p=0.0045 tolb, p=0.00032 glib, 0.022 gliz, t-test). n of preps: 4 (CTR); 3 (tolb); 2 (glib); 3 (gliz); 5 (CTR + fsk); 3 (tolb + fsk); 3 (glib + fsk); 2 (gliz + fsk). n, number of cells. (**c**) Fraction of flash events for experiments in (**b**); Kruskal-Wallis/Dunn Test against ctrl/no fsk: p=0.015 tolb, p=0.001 glib, p=0.097 gliz, and against control +fsk: p=0.07 tolb; p=0.002 glib; p=0.14 gliz;); n, number of cells. (**d**) Cumulative frequency histograms and medians (insets) of NPY release times for (**b--c**). Differences vs control are significant in the absence of fsk: p=9.1\*10^−4^ tolb, p=0.003 glib, p=0.015 gliz, Kolmogorov-Smirnov test). Insets show NPY release times for 38 (CTR), 74 (tolb), 79 (glib), 95 (gliz) events and inset on the right for 111 (CTR), 104 (tolb), 127 (glib) and 54 (gliz) events in presence of fsk. (**e**) Cartoon of the experimental design in (**f--h**). Cells were bathed in 10 mM glucose, 2 µM fsk, 50 µM diazoxide and acutely exposed to sulfonylureas (500 µM tolb, 100 µM glib or 100 µM gliz) during the recording period. (**f**) Exocytosis in presence of fsk (2 µM) for flash events (color) and full fusions (white). Differences are not significant (p=0.16 Kruskal Wallis test). n, number of cells. (**g**) Fraction of flash events for experiments in (**f**). Differences are not significant (p=0.98 Kruskal Wallis test). (**h**) Cumulative frequency histograms and medians (inset) of NPY release times for (**f--g**). Inset shows NPY release times for 111 (CTR), 68 (tolb), 34 (glib) and 31 (gliz) events.](elife-41711-fig5){#fig5}

Sulfonylureas also bind to SUR1 in the plasma membrane, which leads to rapid closure of K~ATP~ channels, depolarization and exocytosis. We tested the involvement of SUR1 by applying sulfonylureas acutely, which is expected to activate SUR1 in the plasma membrane but not Epac the cytosol ([Figure 5e](#fig5){ref-type="fig"}). Reduced diazoxide (50 µM) prevented glucose-dependent exocytosis but still allowed acute stimulation of exocytosis by sulfonylureas. Under these conditions, the fraction of flash-associated exocytosis events ([Figure 5f--g](#fig5){ref-type="fig"}) and the NPY release times ([Figure 5h](#fig5){ref-type="fig"}) were similar to control (stimulation with elevated K^+^) for all three sulfonylureas. Taken together, the data suggest that sulfonylureas must enter the cytosol to affect fusion pore behavior, and that this effect is not mediated by the plasma membrane SUR. We excluded the possibility that sulfonylureas affect the fluorescence signal indirectly, by altering granule pH ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Moreover, an EGFP-tagged SUR1 (EGFP-SUR1) expressed in INS-1 cells did not localize to exocytosis sites or affect fusion pore behavior ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). We therefore conclude that sulfonylureas affect fusion pore behavior through Epac2.

Dynamin and amisyn-controlled restriction of the fusion pore is cAMP-dependent {#s2-6}
------------------------------------------------------------------------------

The proteins dynamin and amisyn have previously been implicated in fusion pore regulation in β-cells ([@bib78]; [@bib22]). To understand how these proteins behave around the release site, we expressed EGFP-tagged dynamin1 ([Figure 6a](#fig6){ref-type="fig"}) or mCherry-tagged amisyn ([Figure 6b](#fig6){ref-type="fig"}) together with a granule marker in INS-1 cells, and stimulated exocytosis with elevated K^+^. In the presence of fsk, both of the two fluorescent proteins were recruited to the granule site during membrane fusion ([Figure 6c,f](#fig6){ref-type="fig"}, and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Expression of both proteins was about 2--4 fold compared with endogenous levels ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), and markedly increased the NPY release times ([Figure 6d, g](#fig6){ref-type="fig"}) and flash-associated exocytosis events ([Figure 6e,h](#fig6){ref-type="fig"}). Addition of the Epac inhibitor ESI09 prevented recruitment of both dynamin1 and amisyn during flash events and reduced flash events and NPY release times below control ([Figure 6c--h](#fig6){ref-type="fig"}). In the absence of fsk, expression of the two proteins had no effect on fusion pore behavior, and only amisyn (but not dynamin1) was recruited to the exocytosis site ([Figure 6i--n](#fig6){ref-type="fig"}). When Epac was activated with S223 (no fsk), dynamin1 and amisyn were recruited during flash events, and NPY release times and flash events were increased for both proteins ([Figure 6i--n](#fig6){ref-type="fig"}). The data suggest that dynamin1 and amisyn are acutely recruited to the exocytosis site, where they participate in cAMP-dependent fusion pore restriction.

![Fusion pore regulation by dynamin1 and amisyn is cAMP-dependent.\
(**a--b**) Example image sequence of transient recruitment of dynamin1-GFP (a, lower) or mCherry-amisyn (b, lower) to granules (upper, labeled with NPY-tdmOrange2 or NPY-EGFP) during K^+^-stimulated exocytosis in presence of forskolin. (**c**) Average time course (± SEM) of dynamin1-GFP (dyn) fluorescence during 34 flash-type exocytosis events (red) and eight full-fusion type events (black) in presence of forskolin; and nine flash events in presence of fsk + ESI09 (blue); data points represent average of five frames and time is relative to the flash onset in the granule signal. (**d**) Cumulative frequency histograms and medians (inset, with p for Kolmogorov-Smirnov test) of NPY release times in presence of fsk in cells expressing dynamin1-EGFP (red), dynamin with added ESI09 (blue) or control (black). 119 (CTR), 42 (dyn), 24 (dyn + ESI09) events. n of preps: 5 (C + fsk); 1 (dyn); 2 (dyn + ESI-09). (**e**) Fraction of flash events in (**d**). n, number of cells, p for Kruskal-Wallis/Dunns test. (**f**) Average time course (± SEM) of mCherry-amisyn (amis) fluorescence (red n = 274 flash events; black n = 46 full fusion events) or in presence of fsk + ESI09 (blue; n = 56 flash events). (**g**) Cumulative frequency histograms and medians (inset, with Kolmogorov-Smirnov test) of NPY release times in cells expressing mCherry-amisyn, amysin with ESI09, or control; fsk was present. 213 (CTR), 320 (amisyn), and 90 (amis +ESI09) events. n of preps: two for each. (**h**) Fraction of flash events in (**g**); p for Kruskal-Wallis/Dunn test. n, number of cells. (**i**) As in c, but without forskolin for control (black), dynamin (red), and dynamin with S223 (green); n = 37 flash events, n = 39 full fusion events for dyn and n = 40 flash events for dyn +S223. (**j--k**) As in (**d--e**), but for 38 (ctrl, black), 76 (dynamin1, red) and 55 (Dyn + S223, green) events in the absence of forskolin. n of preps: 4 (C-fsk); 2 (dyn); 2 (dyn + S223). (**l**) As in f, but without forskolin present; 65 flash events (red) and 73 full fusion events (black) for amisyn, and 154 flash events for amisyn + S223 (green). (**m--n**) As in (**g--h**), but for 123 (ctrl, black), 138 (amisyn, red) and 174 (amis + S223, green) events in the absence of forskolin. n of preps: 1 (C-fsk); 2 (amis); 2 (amis + S223).](elife-41711-fig6){#fig6}

Discussion {#s3}
==========

cAMP-dependent signaling restricts fusion pore expansion and promotes kiss-and-run exocytosis in β-cells ([@bib33]) and neuroendocrine cells ([@bib20]; [@bib53]) (but see [@bib34]). We show here that the cAMP-mediator Epac2 orchestrates these effects by engaging dynamin and perhaps other endocytosis-related proteins at the release site ([Figure 7](#fig7){ref-type="fig"}). Since the fusion pore acts as a molecular sieve, the consequence is that insulin and other peptides remain trapped within the granule, while smaller transmitter molecules with para- or autocrine function are released ([@bib56]; [@bib52]; [@bib75]; [@bib48]). Incretin signaling and Epac activation therefore delays, or altogether prevents insulin secretion from individual granules, while promoting paracrine intra-islet communication that is based mostly on release of small transmitter molecules.

![Summary of fusion pore characteristics.\
Fraction of events with restricted fusion pores, NPY release time and exocytosis rate for Epac2 KO (first column), controls (second column) and with Epac2 overexpression (third column) in absence (upper rows) and presence of tolbutamide (bottom rows). Changes in exocytosis are compared to controls without (left half columns) or with (right half columns) forskolin. See [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"} for details.\
10.7554/eLife.41711.015Figure 7---source data 1.](elife-41711-fig7){#fig7}

Paradoxically, two clinically important classes of antidiabetic drugs, GLP-1 analogs and sulfonylureas, activate Epac in β-cells and caused restriction of the fusion pore. Sulfonylureas have long been known to stimulate insulin secretion by binding to SUR1, which results in closure of K~ATP~ channels and depolarization ([@bib36]). The drugs also accelerate PKA-independent granule priming in β-cells, which may involve activation of intracellularly localized SUR1 ([@bib25]). Our data indicate that sulfonylureas exert a third mode of action that leads to the restriction of the fusion pore and therefore limits insulin release. Two pieces of evidence suggest that SUR1 is not involved in the latter. First, acute exposure to sulfonylureas had no effect on fusion pore behavior, although it blocks K~ATP~ channels (indicating SUR1 activation). Only long-term exposure to sulfonylurea resulted in restricted fusion pores, likely because it allowed the drugs to enter the cytoplasm. Second, we could not detect enrichment of SUR1 at the granule release site, which precludes any direct role of the protein in fusion pore regulation. Sulfonylurea compounds have been shown to allosterically stabilize the cAMP-dependent activation of Epac ([@bib73]; [@bib37]). Our finding that sulfonylurea caused fusion pore restriction in the absence of forskolin indicates that basal cAMP concentrations are sufficient for this effect. Since gliclizide binds the CNB1 domain without activating it ([@bib73]) and still restricts the fusion pore, Epac localization at the granule site ([@bib4]) may be enough to regulate the downstream proteins (e.g. dynamin and amisyn). It can further be speculated that the competing stimulatory (via exocytosis) and inhibitor effects (via the fusion pore) of sulfonylureas on insulin secretion, contribute to the reduction in sulfonylurea effectiveness with time of treatment. Long-term treatment with GLP-1 analogs disturbs glucose homeostasis ([@bib2]), and combination therapy of sulfonylurea and DPP4 inhibitors (that elevate cAMP) has been shown to lead to severe hypoglycemia ([@bib86]), an effect that likely depends on Epac ([@bib74]).

Epac mediates the PKA-independent stimulation of exocytosis by cAMP ([@bib68]) and our data suggests it may affect both priming and fusion pore restriction. This effect is rapid ([@bib25]), suggesting that Epac is preassembled at the site of the secretory machinery. Indeed, Epac concentrates at sites of docked insulin granules ([@bib4]), and forms functionally relevant complexes with the tethering proteins Rim2 and Piccolo ([@bib27]). However, the amount of Epac2 present at individual release sites did not correlate with fusion pore behavior, which may indicate that the protein acts indirectly by activating or recruiting other proteins. Indeed, we show here that recruitment of two other proteins, dynamin and amisyn, depends on cAMP and Epac. Other known targets of Epac are the small GTPases Rap1 and R-Ras, for which Epac is a guanine nucleotide exchange factor (GEF). Rap1 is expressed on insulin granules and affects insulin secretion both directly ([@bib70]), and by promoting intracellular Ca^2+^-release following phospholipase-C activation ([@bib24]). R-Ras is an activator of phosphoinositide 3-kinase ([@bib55]). By altering local phosphoinositide levels, Epac could therefore indirectly affect exocytosis via recruitment of C2-domain proteins such as Munc13 ([@bib44]), and fusion pore behavior by recruitment of the PH-domain containing proteins dynamin and amisyn ([@bib60]; [@bib1]).

An unresolved question is whether pore behavior is controlled by mechanisms that promote pore dilation, or that instead prevent it. Dynamin causes vesicle fission during clathrin-dependent endocytosis ([@bib54]), and since dynamin is present at the exocytosis site and required for the kiss-and-run mode ([@bib41]; [@bib78]; [@bib77]), it may have a similar role during transient exocytosis. An active scission mechanism is also suggested by the finding that granules loose some of their membrane proteins during transient exocytosis ([@bib78]; [@bib58]). Capacitance measurements have shown that fusion pores initially flicker with conductances similar to those of large ion channels, before expanding irreversibly ([@bib51]). This could result from pores that are initially stabilized through unknown protein interactions and that eventually give way to uncontrolled expansion. However, scission mechanisms involving dynamin can act even when the pore has dilated considerably beyond limit of reversible flicker behavior ([@bib71]; [@bib76]; [@bib88]; [@bib8]), and even relatively large granules retain their size during fusion-fission cycles ([@bib52]; [@bib51]). Separate mechanisms may therefore operate, one that prevents pore dilation by actively causing scission, similar to the role of dynamins in endocytosis, and another by shifting the equilibrium between the open and closed states of the initial fusion pore. Curvature-sensitive proteins are particularly attractive for such roles since they could accumulate at the neck of the fused granule; such ring-like assemblies that have indeed been observed for the Ca^2+^-sensor synaptotagmin ([@bib82]). Active pore dilation has also been proposed to be driven by crowding of SNARE proteins ([@bib85]) and α-synuclein ([@bib50]).

β-cell granules contain a variety of polypeptides (insulin, IAPP, chromogranins) and small molecule transmitter molecules (GABA, nucleotides, 5HT) that have important para- and autocrine functions within the islet ([@bib16]; [@bib19]). Insulin modulates its own release by activating β-cell insulin receptors ([@bib49]), stimulates somatostatin release ([@bib81]), and inhibits glucagon secretion ([@bib61]). Insulin secretion is also inhibited by IAPP/amylin and chromogranin cleavage products such as pancreastatin ([@bib16]). Of the small transmitters, GABA inhibits glucagon secretion from α-cells ([@bib63]) and enhances insulin secretion ([@bib72]), and tonic GABA signaling is important for the maintenance of β-cell mass ([@bib72]). Adenine nucleotides cause β-cell depolarization, intracellular Ca^2+^-release and enhanced insulin secretion ([@bib46]; [@bib42]), but also negative effects have been reported ([@bib64]; [@bib59]). Paracrine purinergic effects also coordinate Ca^2+^ signaling among β-cells ([@bib35]), stimulate secretion of somatostatin from δ-cells ([@bib15]), and target islet vasculature and macrophages as part of the immune system ([@bib83]). By selectively allowing small molecule release, Epac/cAMP-dependent fusion pore restriction is expected to alter both the timing and the relative volume of peptidergic vs. transmitter signaling. Given that granule priming and islet electrical activity are regulated on a second time scale, even small delays between these signals can be envisioned to affect the ratio of insulin to glucagon secretion. As illustrated by the recent finding of altered fusion pore behavior in type-2 diabetes ([@bib22]), Epac-dependent fusion pore regulation may have profound consequences for islet physiology and glucose metabolism in vivo.

Materials and methods {#s4}
=====================

  Reagent or Resource                           Designation                       Source of Reference    Identifiers                                                     Additional Information
  --------------------------------------------- --------------------------------- ---------------------- --------------------------------------------------------------- -----------------------------------------------------------
  Strain, strain background (Adenovirus)        NPY-Venus                         P Rorsman (Oxford)                                                                     
  Strain, strain background (Adenovirus)        NPY-tdmOrange2                    this paper                                                                             See Constructs in Materials and methods
  Genetic reagent (*Mus musculus*)              *Rapgef4* KO and WT               ([@bib47])                                                                             
  Cell line (*Rattus norvegicus domesticus*)    INS-1 Clone 832/12                ([@bib38])             RRID:[CVCL_7226](https://scicrunch.org/resolver/CVCL_7226)      H Mulder (Malmö)
  Transfected construct (*Mus musculus*)        EGFP-Epac2                        ([@bib40])             1068                                                            
  Transfected construct (*Homo sapiens*)        NPY-tdmOrange2                    ([@bib28])             1140                                                            
  Transfected construct (*Rattus norvegicus*)   P2X~2~-mRFP1                      ([@bib56])             1226                                                            
  Transfected construct (*Homo sapiens*)        NPY EGFP mCherry                  this paper                                                                             See Constructs in Materials and methods
  Transfected construct (*Homo sapiens*)        Cherry2-amisyn                    This paper             NM_001351940.1; 1286                                            See Constructs in Materials and methods
  Transfected construct (*Homo sapiens*)        dynamin1-GFP                      W Almers (Portland)    1342                                                            
  Transfected construct (*Homo sapiens*)        NPY EGFP                          W Almers (Portland)    1008                                                            
  Biological sample (*Homo sapiens*)            Human pancreatic islets           ([@bib31])                                                                             Nordic Network for Clinical Islet Transplantation Uppsala
  Antibody                                      Rabbit polyclonal anti-amisyn     ab153974 abcam                                                                         1/50
  Antibody                                      Rabbit monoclonal anti-dynamin1   ab52852 abcam          [PMID:28171750](https://www.ncbi.nlm.nih.gov/pubmed/28171750)   1/50
  Chemical compound, drug                       Cell dissociation buffer          Thermo Fisher          13150016                                                        
  Chemical compound, drug                       Trypsin solution                  Thermo Fisher          12604--021                                                      
  Chemical compound, drug                       Lipofectamine 2000                Thermo Fisher          11668--019                                                      
  Chemical compound, drug                       Forskolin; Fsk                    Sigma-Aldrich          F6886                                                           
  Chemical compound, drug                       Polylysine                        Sigma-Aldrich          P5899                                                           
  Chemical compound, drug                       Exendin-4; Ex4                    Anaspec (Fremont CA)   AS-24463                                                        
  Chemical compound, drug                       Diazoxide                         Sigma-Aldrich          D9035                                                           
  Chemical compound, drug                       BSA                               Sigma-Aldrich          F0804                                                           
  Chemical compound, drug                       RPMI 1640                         SVA                    992680                                                          
  Chemical compound, drug                       L-Glutamine                       Hyclone                SH30034.01                                                      
  Chemical compound, drug                       Tolbutamide; tolb                 Sigma-Aldrich          64-77-7                                                         
  Chemical compound, drug                       Glibenclamide; glib               Hoechst                                                                                
  Chemical compound, drug                       Gliclizide; gliz                  Sigma-Aldrich          21187-98-4                                                      
  Chemical compound, drug                       S223                              Biolog                 B 056--01                                                       
  Software, algorithm                           MetaMorph                         Molecular Devices                                                                      

Cells {#s4-1}
-----

Human islets were obtained from the Nordic Network for Clinical Islet Transplantation Uppsala ([@bib31]) under full ethical clearance (Uppsala Regional Ethics Board 2006/348) and with written informed consent. Isolated islets were cultured free-floating in sterile dishes in CMRL 1066 culture medium containing 5.5 mM glucose, 10% fetal calf serum, 2 mM L-glutamine, streptomycin (100 U/ml), and penicillin (100 U/ml) at 37°C in an atmosphere of 5% CO~2~ up to 2 weeks. Prior to imaging, islets were dispersed into single cells by gentle agitation using Ca^2+^-free cell dissociation buffer (Thermo Fisher Scientific) supplemented with 10% (v/v) trypsin (0.05% Thermo Fisher Scientific). INS1-cells clone 832/13 ([@bib38]) were maintained in RPMI 1640 (Invitrogen) with 10 mM glucose, 10% fetal bovine serum, streptomycin (100 U/ml), penicillin (100 U/ml), Sodium pyruvate (1 mM), and 2-mercaptoethanol (50 μM). The ins1 832/13 cells were screened by PCR and found negative for mycoplasma.

Mouse islets were isolated from 5 to 12 months old WT and Epac2^-/-^ ([@bib47]) (*Rapgef4*^-/-^) animals. The Epac2 deletion involves exons 12--13, which include the high-affinity cAMP binding domain present in all Epac2 isoforms, in contrast to previously reported knockout strain ([@bib70]), which only lacks the Epac2A isoform. The mice were anesthetized and the pancreas dissected out and cleared from fat and connective tissue in ice-cold Ca5 solution (in mM 125 NaCl, 5KCl, 1.2 MgCl~2~, 1.28 CaCl~2~, 10 HEPES; pH 7.4 with NaOH). Pancreas was injected with Collagenase P (1 mg/ml) and cut into small pieces before mechanical dissociation (7 min at 37°C). BSA was added immediately and islets were washed 3X with ice cold Ca5 buffer with BSA. Islets were dispersed into single cells using Ca^2+^-free cell dissociation buffer (supplemented with 10% (v/v) trypsin) and gentle agitation. Dispersed cells were sedimented by centrifugation, resuspended in RPMI 1640 medium (containing 5.5 mM glucose, 10% fetal calf serum, 100 U/ml penicillin and 100 U/ml streptomycin).

The cells were plated onto 22 mm polylysine-coated coverslips and were transduced the next day using adenovirus (human and mouse cells) or transfected the same day with plasmids (INS1 cells, using Lipofectamine2000, Invitrogen) encoding the granule markers NPY-Venus, NPY-EGFP or NPY-tdOrange. Imaging proceeded 24--36 hr later.

Constructs {#s4-2}
----------

The open-reading frame of human amisyn (NM_001351940.1) was obtained as a synthetic DNA fragment (Eurofins, Germany) and was cloned into pCherry2 C1 (Addgene, plasmid nr 54563) by seamless PCR cloning. The linker between Cherry2 and amisyn translates into the peptide SGLRSRAQASNSAV. The plasmid N1 NPY-EGFP-mCherry coding for NPY-linker(TVPRARDPPVAT)-EGFP-linker(KRSGGSGGSGGS)-mCherry was made by seamless PCR cloning. The correct open-reading frame of both Cherry2-linker-amisyn and NPY-EGFP-mCherry was confirmed by Sanger sequencing (Eurofins, Germany). The NPY-tdOrange2 adeno virus was made using the RAPAd vector system (Cell Biolabs, San Diego). NPY-tdOrange2 ([@bib28]) was cloned into the pacAd5 CMVK-NpA Shuttle plasmid (Cell Biolabs). Virus was produced in HEK293 cells and isolated according to the instructions of the manufacturer (Cell Biolabs).

Solutions {#s4-3}
---------

Cells were imaged in (mM) 138 NaCl, 5.6 KCl, 1.2 MgCl~2~, 2.6 CaCl~2~, 10 D-glucose 5 HEPES (pH 7.4 with NaOH) at 32--34°C. Exocytosis was evoked with high 75 mM K^+^ (equimolarly replacing Na^+^), applied by computer-timed local pressure ejection through a pulled glass capillary. For K^+^-induced exocytosis, spontaneous depolarizations were prevented with 200 µM diazoxide (50 µM for [Figure 5e--h](#fig5){ref-type="fig"}). In [Figure 5e--h](#fig5){ref-type="fig"}, exocytosis was evoked by sulfonylureas (500 µM tolbutamide, 200 µM glibenclamide or 200 µM gliclizide). For electrophysiology, glucose was reduced to 3 mM, and the electrodes were filled with (mM) 125 CsCl, 10 NaCl, 1.2 MgCl~2~, 5 EGTA, 4 CaCl~2~, 3 Mg-ATP, 0.1 cAMP, 10 HEPES (pH 7.15 using CsOH).

Immunocytochemistry {#s4-4}
-------------------

To quantify the overexpression, INS-1 cell were transfected with either Cherry2-amisyn or Dynamin1-GFP, fixed 24 hr later in 3.8% formaldehyde in phosphate-buffered saline (PBS) for 30 min at 25°C and washed in PBS. The cells were permeabilized in 0.2% Triton X-100 in PBS for 5 min and washed in PBS. Blocking was done using 5% FBS in PBS for 1--2 hr at 25°C. Cells were then incubated with a primary antibody (anti-Dynamin1, ab52852 abcam or anti-Amisyn, ab153974 abcam) both diluted 1/50 in 5% FCS in PBS over night at 4°C and washed again in PBS. Incubation with secondary antibody (Alexa Fluor 488 anti-rabbit or Alexa Fluor 555 anti-rabbit, Invitrogen) diluted 1/1000 in 5% FCS in PBS was performed for 1 hr at 25°C and subsequently the cells were washed in PBS.

TIRF microscopy {#s4-5}
---------------

Human cells were imaged using a lens-type total internal reflection (TIRF) microscope, based on an AxioObserver Z1 with a 100x/1.45 objective (Carl Zeiss). TIRF illumination with a calculated decay constant of \~100 nm was created using two DPSS lasers at 491 and 561 nm (Cobolt, Stockholm, Sweden) that passed through a cleanup filter (zet405/488/561/640x, Chroma) and was controlled with an acousto-optical tunable filter (AA-Opto, France). Excitation and emission light were separated using a beamsplitter (ZT405/488/561/640rpc, Chroma) and the emission light chromatically separated (QuadView, Roper) onto separate areas of an EMCCD camera (QuantEM 512SC, Roper) with a cutoff at 565 nm (565dcxr, Chroma) and emission filters (ET525/50 m and 600/50 m, Chroma). Scaling was 160 nm per pixel.

INS1 and mouse cells were imaged using a custom-built lens-type TIRF microscope based on an AxioObserver D1 microscope and a 100x/1.45 NA objective (Carl Zeiss). Excitation was from two DPSS lasers at 473 nm and 561 nm (Cobolt), controlled with an acousto-optical tunable filter (AOTF, AA-Opto) and using dichroic Di01-R488/561 (Semrock). The emission light was separated onto the two halves of a 16-bit EMCCD camera (Roper Cascade 512B, gain setting at 3800 a.u. throughout) using an image splitter (DualView, Photometrics) with ET525/50 m and 600/50 m emission filters (Chroma). Scaling was 100 nm per pixel for INS-1 experiments and 160 nm for mouse cells. The frame rate was 10 frames\*s^−1^, with 100 ms exposures.

Image analysis {#s4-6}
--------------

Exocytosis events were identified manually based on the characteristic rapid loss of the granule marker fluorescence (most fluorescence lost within 1--2 frames) in cells which exhibited minimum of 1 event/cell (except mouse cells, where all cells were included). Events were classified as flash events if they exhibited an increase in the fluorescence signal before the rapid loss of the granule fluorescence. The NPY release times were obtained for both types of events by non-linear fitting with a discontinuous function in Origin as described previously ([@bib28]). Protein binding to the release site (ΔF/S) was measured as described previously ([@bib29]).

Electrophysiology {#s4-7}
-----------------

ATP release was measured in INS1 cells expressing RFP-tagged P2X~2~ receptor ([@bib56]). Cells were voltage-clamped in whole-cell mode using an EPC-9 amplifier and PatchMaster software (Heka Elektronik, Lambrecht, Germany) with patch-clamp electrodes pulled from borosilicate glass capillaries that were coated with Sylgard close to the tips, and fire-polished (resistance 2--4 MΩ). The free \[Ca^2+^\] was calculated to be 600 nM (WEBMAXC standard) and elicited exocytosis that was detected as P2X~2~-dependent inward current spikes. Currents were filtered at 1 kHz and sampled at 5 kHz. Spike analysis was performed using automated program for amperometric recordings in IGOR Pro ([@bib67]), with the threshold set at eight times the RMS noise during event-free section of recording.

Statistics {#s4-8}
----------

Data are presented as mean ± SEM unless otherwise stated. Statistical significance was tested (unless otherwise stated) and is indicated by asterisks (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). The not normally distributed exocytosis rates and ratios of flash events were tested with Kruskal Wallis with post hoc Dunn test and NPY release times were tested with Kolmogorov-Smirnov test.
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Thank you for submitting your article \"Fusion pore regulation by Epac2/cAMP controls cargo release during insulin exocytosis\" for consideration by *eLife*. Your article has been reviewed by Vivek Malhotra as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Ling-Gang Wu (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this work the regulation of fusion pore dynamics in pancreatic β-cells is studied. The authors use human pancreatic β-cells for key first experiments, and subsequently from INS-1 cells and the Epac2 knockout mouse. Although it has been previously reported that Epac2 is directly involved in exocytosis at the exocytotic machinery, the precise mechanisms by which Epac2 regulates insulin exocytosis are poorly understood. The results suggest that cAMP and sulfonylureas restrict the fusion pore opening thereby limiting the release of insulin. Finally, the data further suggest that dynamin and amysin are part in the fusion pore restriction and that recruitment of these proteins to the release site is cAMP-dependent. The work adds new information on the role of Epac2 in fusion pore dynamics regarding the release from β-cells of not only insulin but also many other signaling smaller nucleotides.

There are several concerns as outlined below and we outline experimental data that should be included in the revised manuscript.

Essential revisions:

The heterogeneity among cells from different human donors is wide, and it can be argued whether results will hold if the authors increase the number of donors in their study. Moreover, the data from INS-1cells (rat islet origin and not human) require considering differences between human and rodent β-cells. It is essential that the key experiments in Figure 1 and the dynamin/amysin experiments in Figure 6 are repeated in the human cell line EndoC.

The authors do not really show the link between cAMP and dynamin/amysin. What mechanisms are involved in this process? The authors should address this by perhaps a speculative model in their discussion.

Abstract, the conclusion is wrong: cAMP elevation leads to pore expansion and peptide release, but not when Epac2 is inactivated pharmacologically or in Epac2^-/-^ mice. Conversely, overexpression of Epac2 impedes pore expansion. Based on the data, the conclusion might be: cAMP elevation restricts pore and leads to a slower expansion of the fusion pore and peptide release, but not when Epac2 is inactivated pharmacologically or in Epac2^-/-^ mice. Consistently, overexpression of Epac2 impedes pore expansion.

The complete release of NPY proceeds via full collapse fusion as shown in Figure 1(B) and in the text (Introduction), but according to reference (Shin et al., 2018), the vesicles can maintain the omega-shaped structures even after complete NPY release, and the pores can constrict after the complete release. Full-collapse is not observed for dense-core vesicle fusion in chromaffin cells (Shin et al., 2018). In addition, the fusion pore does not have to be larger than 10-30 nm for complete NPY release, because EGFP size is only 3.7nm as stated. The diagram in Figure 1(B) should be modified accordingly to avoid extrapolation from a pore more than 3.7 nm to full collapse fusion, and, \"fusion pore lifetime\" should be changed to \"NPY release time\" or other proper terms both in the legends and the main text. The methods used by the authors do not detect fusion pore lifetime, but only the NPY release time course (see Shin et al., 2018 for imaging of the fusion pore lifetime).

What is the reason that authors restricted exocytosis events to the rapid loss of the granule marker fluorescent (1-2 frames)? What about granule marker loss within 3-10 frames or \>10 frame? Please clarify why these events are excluded. On the other hand, in Figure 6a, the release time of the NPY after flash takes more than 2 seconds with multiple frames (obviously \>4 frames). This is inconsistent with the author\'s criteria of exocytosis events with the rapid loss within 1-2 frames. Please show the frame rate of all experiments since the different frame rates may generate different fraction of flash events vs full fusion events.

Rapid NPY spot fluorescence decrease can also be due to vesicle undocking (docked vesicle leaving the docking site), rather than fusion as in Figure 1A. The possibility of undocking should be ruled out by control experiments. A control experiment can be co-expressing pH-sensitive vesicular protein or adding dye in the bath solution to indicate fusion.

In subsection "cAMP-dependent fusion pore restriction is regulated by Epac but not PKA", the authors state that PKA inhibition with Rp8-Br-cAMPS decreases exocytosis \~40% but not the fraction of flash events which is shown in Figure 1F. Then the percentage of flash events should be \>80% in Figure 1D for fsk+RP-8, but the flash percentage is similar as fsk alone with \~60-65%. How is this possible? This needs to be clarified to support the conclusion that Epac rather than PKA is responsible for cAMP-dependent fusion pore regulation.

At the end of Introduction, the authors write that activation of Epac2 via GLP-1 and sulfonylurea will hinder full fusion and that this is \"expected to reduce their full fusion as insulin secretagogoues\". However, there are no data available in this study (or in published elsewhere) showing that addition of GLP-1 or sulfonylurea will reduce insulin secretion. How do the authors validate the importance of their study? Is glucose stimulated insulin secretion decreased in the cells (Figure 2) overexpressing Epac2? What about Epac2 and insulin secretion in EndoC cells?

The efficiency of the overexpression is not shown. What is the mRNA and protein levels of Epac2 (Figure 2), amysin and dynamin (Figure 6) after overexpression?

The authors have not performed the proper statistics for the data. A simple t-test is not enough when comparing multiple conditions. At least one-way ANOVA with ad hoc-test for multiple comparison.

The authors used Epac2 KO mice established in Kopperud et al. 2017, in which the characteristics of microvascular permeability of these mice was examined. However, the characteristics regarding glucose homeostasis including insulin secretion were not well studied in the paper. Furthermore, other lines of Epac2 KO mice have already been established and analyzed. The authors need to examine at least the insulin secretory profiles in the Epac2 KO mice used in this study in vivo and in vitro, and discuss them by referring to the previous studies using other KO strains.

Figure 2 shows that the percentage of flash events is increased by overexpression of Epac2. However, the actual number of flash events is not changed but full fusion events are decreased (Figure 2B), resulting in a decrease in the total number of fusion events (Figure 2A). In Figure 1, Epac activation by S223 increases the total number of exocytotic events by increasing flash events without changing the number of full fusion events. It seems that the fusion pore-regulating mechanism is different between these two conditions. Any thoughts on this issue?

In Figure 4, the total number of exocytotic events is not increased by fsk in Epac2 KO β-cells. However, it is unlikely that cAMP cannot increase the number of exocytotic events in the absence of Epac2, as PKA signaling remains intact. What is the authors\' interpretation of these results?

In Figure 4F and 4G, fsk seems to prolong fusion pore lifetime significantly in both WT and Epac2 KO β-cells, although the authors state that the lifetimes are similar with or without forskolin. This should be modified.

In Figure 5, glib, tolb and gliz show similar effects on fusion pore regulation. However, the gliclazide data are inconsistent with the previous reports in which gliclazide among various sulfonylureas does not activate Epac2 (Zhang et al., 2009, Takahashi et al., 2013, Takahashi et al., 2013). The results should be confirmed using β-cells from Epac2 KO mice.

The authors show in Figure 6 that dynamin and amisyn are translocated to the site of exocytosis in a cAMP-dependent manner, and suggest that Epac protein is preassembled at the site of the secretory machinery. The authors also mention the involvement of Epac2 in the recruitment of dynamin and amisyn to the site of exocytosis, based on the observations of the translocation of these proteins by cAMP stimulation, which do not provide sufficient evidence to draw the authors\' conclusion. The authors should show the behaviors of dynamin and amisyn in Epac2 KO β-cells and when Epac is activated pharmacologically.

The significance of the restriction of fusion pore expansion is not clear. Both full fusion and flash events eventually release all contents of the secretory vesicle. Thus, the prolonged fusion pore lifetime means only a few seconds delay in insulin release compared to release of small molecules (or small molecules release a few seconds in advance of the insulin release). Although the authors discuss the roles of these small molecules in autocrine and paracrine signaling in islets, the physiological and pathophysiological relevance of the time difference in the release of insulin and small molecules should be further discussed.

It has previously been shown that there are different modes of insulin exocytosis, based on the dynamics of insulin granules (predocked granules, newcomer granules, etc.) (Shibasaki et al.,2007 and Nagamatsu et al., 2006). Is there any difference in the mode of insulin exocytosis between the present study and the previous reports? The authors might want to discuss the modes of exocytotic events found in the present study in relation to previous studies.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosis\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Vivek Malhotra (Senior Editor), a Reviewing Editor, and three reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) Figure 1B. The drawing of full fusion with a wide concave structure may be subject to error, as recent super-resolution STED imaging shows that fusing dense-core vesicles maintain an omega-shape till the STED resolution limit (Shin et al., 2018; Chiang et al., 2014). We suggest to re-draw the concave shape in Figure 1B as an omega shape with a larger pore than the other omega profile at the left side. This does not mean that full-collapse does not occur in β-cells, but the authors\' data can only say that the fusion pore is larger than NPY-venus.

2\) The reviewer\'s comment: "Figure 2 shows that the percentage of flash events..."

The authors do not respond to the comment properly. The reviewers asked the authors to discuss the mechanisms of the different findings between Figure 2 and Figure 1. This should be reconsidered.

3\) The reviewer\'s comment: "In Figure 5, Glib, tolb and gliz show similar effects..."

The authors have performed the requested experiments, and suggested that Epac2 is required for the effect of gliz on the fusion pore. The result on gliz is different from the previous reports (Zhang et al., 2009; Takahashi et al., 2013). The authors should discuss reasons for the discrepancy.

4\) The reviewer\'s comment: "The role of Eoac2(cAMP-GEFII) in insulin exocytosis..." The authors responded to the comment, but the modified statement has not been incorporated in the text (Introduction).

5\) The reviewer\'s comment: "The source of reagents..." The source is provided, but the source of the Epac2 agonist S223 is missing.

6\) The reviewer\'s comment: The description \"inhibitors of the GLP-1 peptidase\"... In the authors\' response, \"inhibitors of DPP-4 peptidase\" should be \"inhibitors of DPP-4\"(delete\"peptidase\").

10.7554/eLife.41711.021

Author response

> Summary:
>
> In this work the regulation of fusion pore dynamics in pancreatic β-cells is studied. The authors use human pancreatic β-cells for key first experiments, and subsequently from INS-1 cells and the Epac2 knockout mouse. Although it has been previously reported that Epac2 is directly involved in exocytosis at the exocytotic machinery, the precise mechanisms by which Epac2 regulates insulin exocytosis are poorly understood. The results suggest that cAMP and sulfonylureas restrict the fusion pore opening thereby limiting the release of insulin. Finally, the data further suggest that dynamin and amysin are part in the fusion pore restriction and that recruitment of these proteins to the release site is cAMP-dependent. The work adds new information on the role of Epac2 in fusion pore dynamics regarding the release from β-cells of not only insulin but also many other signaling smaller nucleotides.
>
> There are several concerns as outlined below and we outline experimental data that should be included in the revised manuscript.
>
> Essential revisions:
>
> The heterogeneity among cells from different human donors is wide, and it can be argued whether results will hold if the authors increase the number of donors in their study. Moreover, the data from INS-1 cells (rat islet origin and not human) require considering differences between human and rodent β-cells. It is essential that the key experiments in Figure 1 and the dynamin/amysin experiments in Figure 6 are repeated in the human cell line EndoC.

The EndoC line is not available to us, despite a request to the authors. During revision, we instead added data from four additional human donors, so that each of the conditions in Figure 1 now has been measured with 5-7 donors. We do not see strong donor to donor variation with respect to fusion pore behavior, and even average exocytosis is relatively similar between preps from non-diabetic donors (see [Author response image 1](#respfig1){ref-type="fig"} and Gandasi et al., 2018). While there are differences in exocytosis rate between Ins1 and human cells, the effect of forskolin is very similar between the two. Exocytosis roughly doubles, the fraction of flash events shifts from 40 to 60%, and pore lifetimes increase from 0.27 to 0.7s for Ins1 and from 0.3 to 0.9s for human cells. We would also like to point out that Ins1 is a far more established model for insulin exocytosis (at least 1800 papers in PubMed) than EndoC (about 60 papers, of which only 4 studied exocytosis).

![K^+^-stimulated exocytosis in the indicated conditions.\
In (**a**) each symbol represents the average of a donor, in (**b**), each symbol represents one cell.](elife-41711-resp-fig1){#respfig1}

> The authors do not really show the link between cAMP and dynamin/amysin. What mechanisms are involved in this process? The authors should address this by perhaps a speculative model in their discussion.

We now include data demonstrating that pharmacological inactivation of Epac prevents cAMP-dependent recruitment of dynamin and amisyn, and that the specific Epac activator S223 leads to recruitment of these proteins during flash exocytosis even in absence of cAMP raising agents (Figure 6).

We speculate (in the Discussion section) that cAMP/Epac controls the local generation of PIP2, which in turn leads to recruitment of the PH-domain containing proteins dynamin and amisyn:

"Indeed, we show here that recruitment of two other proteins, dynamin and amisyn, depends on cAMP and Epac. Other known targets of Epac are the small GTPases Rap1 and R-Ras, for which Epac is a guanine nucleotide exchange factor (GEF). Rap1 is expressed on insulin granules and affects insulin secretion both directly ^65^, and by promoting intracellular Ca^2+^-release following phospholipase-C activation ^66^. R-Ras is an activator of phosphoinositide 3-kinase ^67^. By altering local phosphoinositide levels, Epac could therefore indirectly affect exocytosis via recruitment of C2-domain proteins such as Munc13 ^68^, and fusion pore behavior by recruitment of the PH-domain containing proteins dynamin and amisyn ^69,70^."

> Abstract, the conclusion is wrong: cAMP elevation leads to pore expansion and peptide release, but not when Epac2 is inactivated pharmacologically or in Epac2^-/-^ mice. Conversely, overexpression of Epac2 impedes pore expansion. Based on the data, the conclusion might be: cAMP elevation restricts pore and leads to a slower expansion of the fusion pore and peptide release, but not when Epac2 is inactivated pharmacologically or in Epac2^-/-^ mice. Consistently, overexpression of Epac2 impedes pore expansion.

We thank the reviewer for pointing out this error, which has been corrected as suggested.

> The complete release of NPY proceeds via full collapse fusion as shown in Figure 1(B) and in the text (Introduction), but according to reference (Shin et al., 2018), the vesicles can maintain the omega-shaped structures even after complete NPY release, and the pores can constrict after the complete release. Full-collapse is not observed for dense-core vesicle fusion in chromaffin cells (Shin et al., 2018). In addition, the fusion pore does not have to be larger than 10-30 nm for complete NPY release, because EGFP size is only 3.7nm as stated. The diagram in Figure 1(B) should be modified accordingly to avoid extrapolation from a pore more than 3.7 nm to full collapse fusion, and, \"fusion pore lifetime\" should be changed to \"NPY release time\" or other proper terms both in the legends and the main text. The methods used by the authors do not detect fusion pore lifetime, but only the NPY release time course (see Shin et al., 2018 for imaging of the fusion pore lifetime).

We agree that long-lived omega-shaped structures cannot be excluded in pancreatic β-cells. This is now acknowledged (Introduction). We have also changed the fusion pore lifetime to NPY release time thorough the figures and text, as suggested.

> What is the reason that authors restricted exocytosis events to the rapid loss of the granule marker fluorescent (1-2 frames)? What about granule marker loss within 3-10 frames or \>10 frame? Please clarify why these events are excluded. On the other hand, in Figure 6a, the release time of the NPY after flash takes more than 2 seconds with multiple frames (obviously \>4 frames). This is inconsistent with the author\'s criteria of exocytosis events with the rapid loss within 1-2 frames. Please show the frame rate of all experiments since the different frame rates may generate different fraction of flash events vs full fusion events.

Detection of events was done by eye, using the criterion that the majority of the signal is lost suddenly (1-2 frames). This is now stated in the Materials and methods section, where we added the following text:

"The frame rate was 10 frames\*s^-1^, with 100 ms exposures" subsection "TIRF microscopy" and "characteristic rapid loss of the granule marker fluorescence (most fluorescence lost within 1-2 frames)" subsection "Image analysis".

In rare cases, a small portion of the signal remained at the release site (as in Figure 6A, note that only every fifth frame is shown). This is apparent in the quantification of the NPY-mOrange signal (now shown in Figure 6---figure supplement 1). There are four possible explanations for the remaining fluorescence, (1) binding of the label to the outside of the cell after complete release (Michael, 2006), (2) kiss and run followed by undocking or re-acidification (Obermüller, 2005), (3) stray light from a nearby granule that did not undergo exocytosis, or (4) rapid undocking (see answer to the next question). We would maintain that the effect of all of this on our flash/no flash ratio measurement is minor. Occasionally, pore lifetimes for no-flash events are overestimated by the fitter, but this would not affect the conclusions of the paper.

> Rapid NPY spot fluorescence decrease can also be due to vesicle undocking (docked vesicle leaving the docking site), rather than fusion as in Figure 1A. The possibility of undocking should be ruled out by control experiments. A control experiment can be co-expressing pH-sensitive vesicular protein or adding dye in the bath solution to indicate fusion.

Undocking is a rare event, 25-100 times less frequently than K^+^-stimulated exocytosis (eg Gandasi et al., 2018). However, control experiments were included in two of our previous papers. Accordingly, NPY-EGFP fluorescence disappears rapidly during exocytosis, while loss of the signal during undocking takes several seconds (Gandasi and Barg,2014; Figure S7). Multiplane confocal imaging also indicated that undocking is very slow, compared with exocytosis/content release (Barg, 2002, Figure 3).

> In subsection "cAMP-dependent fusion pore restriction is regulated by Epac but not PKA", the authors state that PKA inhibition with Rp8-Br-cAMPS decreases exocytosis \~40% but not the fraction of flash events which is shown in Figure 1F. Then the percentage of flash events should be \>80% in Figure 1D for fsk+RP-8, but the flash percentage is similar as fsk alone with \~60-65%. How is this possible? This needs to be clarified to support the conclusion that Epac rather than PKA is responsible for cAMP-dependent fusion pore regulation.

We respectfully disagree. Assuming that PKA only affects the rate of exocytosis (but not fusion pore behavior), we would expect that the fraction of flash events remains constant in presence of the PKA blocker RP-8. This is in fact what is observed (Figure 1D).

> At the end of Introduction, the authors write that activation of Epac2 via GLP-1 and sulfonylurea will hinder full fusion and that this is \"expected to reduce their full fusion as insulin secretagogoues\". However, there are no data available in this study (or in published elsewhere) showing that addition of GLP-1 or sulfonylurea will reduce insulin secretion. How do the authors validate the importance of their study? Is glucose stimulated insulin secretion decreased in the cells (Figure 2) overexpressing Epac2? What about Epac2 and insulin secretion in EndoC cells?

The statement is based on the data in Figure 5 suggesting that SU's restrict fusion pore expansion by the same Epac-dependent mechanism as cAMP. In situations where exocytosis is strongly stimulated (in Figure 5 by SU, K^+^ and ex-4), we observe a relative decrease in exocytosis (and therefore likely also insulin release) rather than an additive effect of SU and fsk. In vivo, SU will primarily stimulate exocytosis by closing K~ATP~ channels and depolarization, but it will be worth investigating whether the stimulatory effect of GLP-1 agonists is affect by longterm SU treatment.

However, our study is focused on the molecular mechanism by which cAMP regulates fusion pore behavior, and we feel that in vivo studies to determine the physiological role of such mechanisms are beyond the scope of the paper. However, there is some evidence that fusion pore regulation by amisyn restricts insulin secretion, and may play a role in human type-2 diabetes (Collins, 2016). We also discuss the possibility that a delay between the release of small transmitters and insulin after Epac activation could be physiologically relevant, for example by influencing para/autocrine signaling in the islet. Such effects might be difficult to detect with traditional insulin secretion measurements, in particular since small molecule release and exocytosis are not considered in secretion measurements.

Regarding EndoC cells, please refer to our comment above.

> The efficiency of the overexpression is not shown. What is the mRNA and protein levels of Epac2 (Figure 2), amysin and dynamin (Figure 6) after overexpression?

We believe that such quantification should be done on single cells, because the transfection only reaches a (varying) fraction of the cells and expression levels vary from cell to cell. We have therefore immunostained INS1 cells that had been transfected with mCherry-amisyn. In these cells we quantified both mCherry-amisyn and immunostaining (anti-amisyn detected with Alexa 488) in a large number of cells, including non-expressing cells (a). As expected, the Alexa fluorescence is higher in transfected cells (b), and there is a near linear relationship between red and green fluorescence (c); the y-axis offset is caused by non-transfected cells that are labeled green but not red, and represents endogenous amisyn expression. From this, we estimate that we worked with cells that overexpress the mCherry-amisyn 2-4 fold compared with endogenous expression. The data also hint that endogenous amisyn may be suppressed by expression of mCherry-amisyn (the average of non-transfected cells is higher than the offset). Similar experiments were done with dynamin1-GFP, and we observed a similar 2-3 fold increase for overexpressed dynamin 1 (d and e). The range of overexpression is similar to a number of other proteins that we have tested (eg syntaxin, CaV1.2), but unfortunately we were unable to source Epac antibodies of sufficient quality to succeed with such quantifications for Epac2.

> The authors have not performed the proper statistics for the data. A simple t-test is not enough when comparing multiple conditions. At least one-way ANOVA with ad hoc-test for multiple comparison.

We thank the reviewer for the suggestion. We now provide one-way ANOVA with posthoc tests (Kruskal Wallis/Dunns) instead of t-tests. The new statistics are described in the methods and legends.

> The authors used Epac2 KO mice established in Kopperud et al. 2017, in which the characteristics of microvascular permeability of these mice was examined. However, the characteristics regarding glucose homeostasis including insulin secretion were not well studied in the paper. Furthermore, other lines of Epac2 KO mice have already been established and analyzed. The authors need to examine at least the insulin secretory profiles in the Epac2 KO mice used in this study in vivo and in vitro, and discuss them by referring to the previous studies using other KO strains.

The Epac2 knockout (KO) mouse used in this study differs from the original and most widely employed strain in that the deletion involves exons 12-13, which encode the high-affinity cAMP binding domain present in all Epac2 isoforms. With the previously generated mouse, a deletion was made in the first exon, thereby eliminating the dominating longest isoform Epac2A, but allowing expression of the shorter isoforms Epac2B and 2C. Indeed, there is evidence that Epac2B is present in mouse pancreatic islets, although it has not been clarified in which cell type(s) the protein is expressed Høivik et al., 2013. We therefore think that it is advantageous to use the mouse in which all Epac2 isoforms have been eliminated. We have added a short description in the methods section explaining the difference between the present mouse and the Epac2A-KO mouse.

A general characterization of the Epac2-KO mouse is ongoing but beyond the scope of this manuscript. Available insulin secretion data do not indicate any striking phenotypical differences from the first published Epac2A-KO strain. We have performed intraperitoneal glucose tolerance tests showing that the mice are slightly glucose intolerant at an age of 10-11 months ([Author response image 2](#respfig2){ref-type="fig"}). This is reminiscent of the glucose intolerance reported for Epac2A-KO following increased metabolic demand induced by e.g. high fat feeding (Song et al., 2013).

Moreover, our analyses show that glucose-stimulated insulin secretion from isolated islets remains intact ([Author response image 3](#respfig3){ref-type="fig"} and [4](#respfig4){ref-type="fig"}), whereas amplification of secretion by cAMP-elevating glucagon is impaired ([Author response image 4](#respfig4){ref-type="fig"}). Although the number of observations are too few for the difference to reach statistical significance, the trend is as expected in light of the function of Epac2 and previously published data from Epac2A-deficient islets. We think that this functional characterization of the mouse would not add much to the present manuscript and think that the data would fit better in a forthcoming manuscript with more extensive phenotypic analyses and functional comparison between Epac2 and Epac1.

![Means ± s.e.m. for blood glucose during intraperitoneal glucose tolerance tests in three 10-11-month-old wild type and Epac2-deficient mice.](elife-41711-resp-fig2){#respfig2}

![Means ± s.e.m. for insulin from isolated islets stimulated by an elevation of the glucose concentration from 3 to 11 mM.\
N=4 mice for each genotype.](elife-41711-resp-fig3){#respfig3}

![Means ± s.e.m. for blood for insulin from isolated islets stimulated by an elevation of the glucose concentration from 3 to 20 mM and addition of 10 nM glucagon.\
N=3 mice for each genotype.](elife-41711-resp-fig4){#respfig4}

> Figure 2 shows that the percentage of flash events is increased by overexpression of Epac2. However, the actual number of flash events is not changed but full fusion events are decreased (Figure 2B), resulting in a decrease in the total number of fusion events (Figure 2A). In Figure 1, Epac activation by S223 increases the total number of exocytotic events by increasing flash events without changing the number of full fusion events. It seems that the fusion pore-regulating mechanism is different between these two conditions. Any thoughts on this issue?

We speculate that Epac becomes inhibitory for exocytosis due to the strong activation of pore restriction with both fsk and exogenous Epac, which competes with the cAMP-dependent acceleration of priming/exocytosis. We believe that this is also the reason for decreased exocytosis in presence of both forskolin and sulfonylurea (Figure 5B). Collins et al., (2016, and comment by Barg and Gucek, 2016) came to a similar conclusion regarding the role of amisyn in type 2 diabetes.

> In Figure 4, the total number of exocytotic events is not increased by fsk in Epac2 KO β-cells. However, it is unlikely that cAMP cannot increase the number of exocytotic events in the absence of Epac2, as PKA signaling remains intact. What is the authors\' interpretation of these results?

We are also surprised by the weak forskolin effect and the explanation is not clear. Since the PKA-dependent effect is slower than the Epac effect on exocytosis (Renström, 1997), it may be speculated that it has not become manifested during the relatively short time course of the experiment. Another possibility is that cAMP is already somewhat elevated in the control situation, since the cells are exposed to 10 mM glucose. Elevated cAMP may lead to PKA activation. It has been demonstrated that the apparent Kd for stimulating granule priming/exocytosis is 5-fold lower for PKA than for Epac (Eliasson, 2003).

> In Figure 4F and 4G, fsk seems to prolong fusion pore lifetime significantly in both WT and Epac2 KO β-cells, although the authors state that the lifetimes are similar with or without forskolin. This should be modified.

Thank you for pointing this out. While the ratios of flash events are equally low, the NPY release time is increased in Epac2KO mice after addition of fsk. We have edited the text accordingly:

"In contrast, exocytosis was not accelerated by forskolin in Epac2^-/-^ cells, and the fraction of flash events was similar with or without forskolin (Figure 4C, F-G)." (subsection "cAMP-dependent fusion pore regulation is absent in Epac2^-/-^ (*Rapgef4*-/-) β-cells").

> In Figure 5, glib, tolb and gliz show similar effects on fusion pore regulation. However, the gliclazide data are inconsistent with the previous reports in which gliclazide among various sulfonylureas does not activate Epac2 (Zhang et al., 2009, Takahashi et al., 2013, Takahashi et al., 2013). The results should be confirmed using β-cells from Epac2 KO mice.

We´ve performed the requested experiment, where we bathed Epac2KO β-cells with gliclizide and monitored exocytosis upon K^+^ depolarization. We observed no increase in either fraction of flash events (a), exocytosis rate (b) or the NPY release times (c), suggesting that Epac2 is required for the effect of gliclazide on the fusion pore. We had already included similar measurements with tolbutamide in the Epac2 KO model (Figure 7 bottom left), indicating that both SU's affect the pore via Epac2.

![](elife-41711-resp-fig5){#respfig5}

> The authors show in Figure 6 that dynamin and amisyn are translocated to the site of exocytosis in a cAMP-dependent manner, and suggest that Epac protein is preassembled at the site of the secretory machinery. The authors also mention the involvement of Epac2 in the recruitment of dynamin and amisyn to the site of exocytosis, based on the observations of the translocation of these proteins by cAMP stimulation, which do not provide sufficient evidence to draw the authors\' conclusion. The authors should show the behaviors of dynamin and amisyn in Epac2 KO β-cells and when Epac is activated pharmacologically.

Unfortunately, we are unable to perform the suggested experiments in Epac2KO cells, without first generating and testing an adenoviral expression system for labeled dynamin and amisyn. We have instead performed experiments in INS1-cells, in which we quantified amisyn or dynamin binding in presence of S223 or ESI-09 to pharmacologically modulate Epac function.

As evident from the new Figure 6, pharmacological inactivation with ESI09 prevents binding of either dynamin1 (c) or amisyn (f) to the release site, resulting in decreased NPY release times (d,g) and fractions of flash events (e,h). Similarly, in absence of fsk, pharmacological activation of Epac2 by S223 results in accumulation of proteins at the release site at the point of fusion (i,l) and longer NPY release times (j,m) together with higher fraction of flashes (k,n). We´ve changed the figure legends accordingly (changes are highlighted in yellow). The results strengthen the conclusion that Epac activation leads to accumulation of dynamin and amisyn at the release site.

> The significance of the restriction of fusion pore expansion is not clear. Both full fusion and flash events eventually release all contents of the secretory vesicle. Thus, the prolonged fusion pore lifetime means only a few seconds delay in insulin release compared to release of small molecules (or small molecules release a few seconds in advance of the insulin release). Although the authors discuss the roles of these small molecules in autocrine and paracrine signaling in islets, the physiological and pathophysiological relevance of the time difference in the release of insulin and small molecules should be further discussed.

The Discussion section has been in part rewritten to strengthen the focus on physiological and pathophysiological relevance.

> It has previously been shown that there are different modes of insulin exocytosis, based on the dynamics of insulin granules (predocked granules, newcomer granules, etc.) (Shibasaki et al.,2007 and Nagamatsu et al., 2006). Is there any difference in the mode of insulin exocytosis between the present study and the previous reports? The authors might want to discuss the modes of exocytotic events found in the present study in relation to previous studies.

While a number of labs have reported crash fusion (all using similar protocols), others have not (Tsuboi and Rutter, 2003; Barg et al., 2002; Michael et al., 2007; Hoppa et al., 2009; Gandasi and Barg, 2014). We recently presented a comprehensive analysis of near-membrane granule behavior in human β-cells, where there was no evidence for crash fusion (Gandasi et al., 2018). The reason why some groups observe crash fusion but others not is unclear. Possible differences include the use of glucose instead of KCl for stimulation (Shibasaki et al., 2007), the duration of the stimulation, and technical issues such as the use of thick cell supports (eg laminin), mistargeting of the granule label to other vesicle types, and label bleaching during long recordings. The latter would give the false appearance of no granule at the site of exocytosis. While this question is interesting and important (and should be settled), we believe that it is not central to the mechanism of fusion pore regulation by Epac and should rather be discussed in a topical review.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Thank you for resubmitting your work entitled \"Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosis\" for further consideration at eLife. Your revised article has been favorably evaluated by Vivek Malhotra (Senior Editor), a Reviewing Editor, and three reviewers.
>
> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) Figure 1B. The drawing of full fusion with a wide concave structure may be subject to error, as recent super-resolution STED imaging shows that fusing dense-core vesicles maintain an omega-shape till the STED resolution limit (Shin et al., 2018; Chiang et al., 2014). We suggest to re-draw the concave shape in Figure 1B as an omega shape with a larger pore than the other omega profile at the left side. This does not mean that full-collapse does not occur in β-cells, but the authors\' data can only say that the fusion pore is larger than NPY-venus.

We thank the reviewer for the suggestion. We have redrawn the final fusion step in Figure 1B as requested.

> 2\) The reviewer\'s comment: "Figure 2 shows that the percentage of flash events..."
>
> The authors do not respond to the comment properly. The reviewers asked the authors to discuss the mechanisms of the different findings between Figure 2 and Figure 1. This should be reconsidered.

This is probably due to its independent action on priming and fusion pore control. With activation (Figure 1; S223) both the effect of priming and the effect on the fusion pore are strongly present. With Epac overexpression only (Figure 2B), there is no effect on the priming, but only on the fusion pore restriction. As we´ve discussed in the response letter, we speculate that Epac, similarly as amisyn, becomes inhibitory for exocytosis due to the strong restriction of the pore with both fsk and exogenous Epac present. We might be under-detecting the restricted fusion pores that close back (kiss-and-run events), which accounts for the observed exocytosis decrease.

We´ve added a short discussion in the Discussion section:" Epac mediates the PKA-independent stimulation of exocytosis by cAMP ^59^ and our data suggests it may affect both priming and fusion pore restriction."

> 3\) The reviewer\'s comment: "In Figure 5, Glib, tolb and gliz show similar effects..."
>
> The authors have performed the requested experiments, and suggested that Epac2 is required for the effect of gliz on the fusion pore. The result on gliz is different from the previous reports (Zhang et al., 2009; Takahashi et al., 2013). The authors should discuss reasons for the discrepancy.

We thank the reviewer for the comment. The mentioned reports state gliz does not activate Epac2A, but it can still bind (only through 1 binding site G114) to the CNB1 domain (Takahashi et al., 2013). We´ve previously shown Epac2 targeting to the plasma membrane doesn't depend on CNB1 domain. The clustering at the granule site however does depend on the CNB1 domain (Alenkvist et al., 2017). Since we speculate that Epac works only as a regulator of downstream proteins (e.g. dynamin 1 and amisyn), the localization at the granule site without activation may explain the restriction of the fusion pores we´ve observed in this study. This is further supported with the data in Figure 2, where overexpression of Epac in absence of forskolin results in a strong restriction of the fusion pores.

We´ve added a short discussion in the Discussion section: "Since gliclizide binds the CNB1 domain without activating it ^54^ and still restricts the fusion pore, Epac localization at the granule site ^39^ may be enough to regulate the downstream proteins (e.g. dynamin and amisyn)."

> 4\) The reviewer\'s comment: "The role of Eoac2(cAMP-GEFII) in insulin exocytosis..." The authors responded to the comment, but the modified statement has not been incorporated in the text (Introduction).

We thank the reviewer for noticing the mistake. We´ve modified the text accordingly.

> 5\) The reviewer\'s comment: "The source of reagents..." The source is provided, but the source of the Epac2 agonist S223 is missing.

We thank the reviewer for the comment. We´ve added the source of S223 (Biolog) to the key resource table.

> 6\) The reviewer\'s comment: The description \"inhibitors of the GLP-1 peptidase\"... In the authors\' response, \"inhibitors of DPP-4 peptidase\" should be \"inhibitors of DPP-4\"(delete\"peptidase\").

We´ve modified the text accordingly.
